Protective Effects of Niclosamide Ethanolamine Against Testosterone-Induced Benign Prostatic Hyperplasia in Rats

Abstract

Benign prostatic hyperplasia is a common urological condition in aging men. The anthelmintic agent niclosamide ethanolamide exhibits a wide range of pharmacological activities. This study aimed to evaluate the protective effect of niclosamide ethanolamide in testosterone propionate-induced benign prostatic hyperplasia in rats along with elucidating the probable mechanism of action by investigating the influence on PPAR-γ and Wnt/β-catenin. 40 male Wistar rats were divided randomly into 4 groups. The healthy (control) group, received daily oral and subcutaneous administration of the vehicle. The Induced (TP) group, received only a daily dose of testosterone propionate 3 mg/kg, SC for 28 days. The treated groups (TP+FIN) and (TP+NE), received a concomitant administration of a daily dose of testosterone propionate along with finasteride 5 mg/kg/day and niclosamide ethanolamide 50 mg/kg/day respectively through oral gavage. Animals were euthanized on day 30 of the experiment and prostate tissue samples were collected to evaluate prostate index, prostate hyperplastic markers by ELISA, and gene expression by RT-qPCR. Results revealed that niclosamide ethanolamide significantly reduced prostate index compared to the induced (TP) group (P<0.0001). The agent nearly normalized BPH markers including 5α-reductase type-2 enzyme, dihydrotestosterone, and PCNA compared to the induced (TP) group (P<0.0001). The agent reduced the tissue level of β-catenin while elevating PPAR-γ to control levels (P<0.05). The current study revealed that NE can help prevent BPH in rats by upregulating the PPAR-γ receptor and inhibiting the Wnt pathway.

Keywords

Benign prostatic hyperplasia - Testosterone propionate - PPAR-gamma - Niclisamide ethanolamide - Beta-catenin - 5α-reductase

Publication History

Received: 16 February 2025

Accepted: 31 March 2025

Article published online:
28 April 2025

• References

• 1 Lee SM, Lee SM, Song J. Effects of Taraxaci Herba (Dandelion) on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Nutrients 2024; 16: 1189
• 2 Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019; 65: 458-464
• 3 Jin BR, Kim HJ, Park SK. et al. Anti-proliferative effects of HBX-5 on progression of benign prostatic hyperplasia. Molecules. 2018; 23: 2638
• 4 Elbaz EM, Amin HAA, Kamel AS. et al. Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways. Inflammopharmacol 2020; 28: 1407-1420
• 5 Lepor H, Kazzazi A, Djavan B. α-Blockers for benign prostatic hyperplasia: the new era. Current opinion in urology 2012; 22: 7-15
• 6 Zhang B, Chen X, Gan Y. et al. Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation. Annals of Translational Medicine. 2021 9.
• 7 Shanmugasundaram D, Dwan C, Wimmer BC. et al. Fucoidan Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Rats. Research and Reports in Urology. 2024: 283-297
• 8 Olokpa E, Moss PE, Stewart LV. Crosstalk between the androgen receptor and PPAR gamma signaling pathways in the prostate. PPAR research 2017; 2017: 9456020
• 9 Kumar R, Coronel L, Somalanka B. et al. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nature communications 2018; 9: 3931
• 10 Jiang H, Li AM, Ye J. The magic bullet: Niclosamide. Frontiers in Oncology 2022; 12: 1004978
• 11 Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacology & therapeutics 1982; 19: 245-295
• 12 Alasadi A, Chen M, Swapna GV. et al. Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer. Cell death & disease 2018; 9: 215
• 13 Elbaz EM, Alshaymaa D, Amany MG. et al. &quot;Canagliflozin Alleviates Experimentally Induced Benign Prostate Hyperplasia in a Rat Model: Exploring Potential Mechanisms Involving Mir-128b/EGFR/EGF and JAK2/STAT3 Signaling Pathways through in Silico and in Vivo Investigations.&quot;. European Journal of Pharmacology 957 2023; 175993
• 14 Ali AG, Gorial F, Mahmood A. The anti-rheumatoid activity of niclosamide in collagen-induced arthritis in rats. Archives of Rheumatology 2019; 34: 426
• 15 Li J, Tian Y, Guo S. et al. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PloS one 2018; 13: e0191469
• 16 Underwood W, Anthony R. AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March. 2020 Mar 2013: 2020-2021
• 17 Ahmed HA, Gatea FK, Hussein ZA. Azilsartan as a preventive agent against cyclophosphamide-induced testicular injury in male rats. Naunyn-Schmiedeberg&apos;s Archives of Pharmacology. 2024: 1-2
• 18 Choi D, Kim J, An J. et al. Amelioration of benign prostatic hyperplasia by costunolide and dehydrocostus lactone in wistar rats. The World Journal of Men&apos;s Health 2019; 39: 315
• 19 Abd-Alhussen JK, Al-Kurdy MJ, Hussein SA. In vivo assessment of the anti-benign prostatic hyperplasia effect of hot ethanolic extract of flax seeds in male rats. Open Veterinary Journal 2024; 14: 1928
• 20 Khorsheed SM, Abu-Raghif AR, Ridha-Salman H. Alleviative effects of combined topical melatonin and rutin on imiquimod-induced psoriasis mouse model. Pharmacia 2024; 71: 1-13
• 21 Mahdi ZA, Gatea FK, Hassan OM. et al. The mitigating effect of a topical preparation of amlodipine on imiquimod-induced psoriasis-like lesion in mice. Research Results in Pharmacology 2024; 10: 143-153
• 22 Hassan Z, Hassan T, Abu-Raghif A. Evaluation the Effectiveness of Phenolic Compound of Salvia Frigida on Induced Atopic Dermatitis in Experimental Mice. Iraqi Journal of Pharmaceutical Sciences 2022; 31: 154-166
• 23 Hussein ZA, Abu-Raghif AR, Fawzi HA. The mitigating effect of para‐hydroxycinnamic acid in bleomycin-induced pulmonary fibrosis in mice through targeting oxidative, inflammatory and fibrotic pathways. Basic & Clinical Pharmacology & Toxicology. 2024
• 24 Faul F, Erdfelder E, Lang AG. et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior research methods 2007; 39: 175-191
• 25 Charan J, Kantharia N. How to calculate sample size in animal studies?. Journal of Pharmacology and Pharmacotherapeutics 2013; 4: 303-306
• 26 Cha JY, Wee J, Jung J. et al. Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. Proceedings of the National Academy of Sciences 2015; 112: 9722-9727
• 27 Srinivasan M, Jewell SD. Quantitative estimation of PCNA, c-myc, EGFR and TGF-α in oral submucous fibrosis—An immunohistochemical study. Oral oncology 2001; 37: 461-467
• 28 Konkol Y, Vuorikoski H, Streng T. et al. Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. Transl Androl Urol 2019; 8: S45-S57
• 29 Campolina-Silva GH, Werneck-Gomes H, Maria BT. et al. Targeting Wistar rat as a model for studying benign, premalignant and malignant lesions of the prostate. Life Sci 242: 117149 2020;
• 30 Tusubira D, Munezero J, Agu PC. et al. “In-vivo and In-silico Studies Revealed the Molecular Mechanisms of Colocasia Esculenta Phenolics as Novel Chemotherapy against Benign Prostatic Hyperplasia via Inhibition of 5α-reductase and α1-adrenoceptor.”. In Silico Pharmacology 2023; 11: 4
• 31 Wang Z, Hu L, Salari K. et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. The Journal of pathology 2017; 243: 457-467
• 32 Jang YJ, Jung HY, Myeong JY. et al. Effects of alginate oligosaccharide on testosterone-induced benign prostatic hyperplasia in orchiectomized rats. Nutrients. 2023; 15: 682
• 33 Chislett B, Chen D, Perera ML. et al. 5-alpha reductase inhibitors use in prostatic disease and beyond. Translational Andrology and Urology 2023; 12: 487
• 34 Cappello F, Bucchieri F, Zummo G. 8 Role of immunohistochemical expression of PCNA and p53 in prostate carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas 2002 Jan 1 (Vol. 2, pp. 359-368). Academic Press;
• 35 Vickman RE, Franco OE, Moline DC. et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian journal of urology 2020; 7: 191-202
• 36 Bauman TM, Vezina CM, Huang W. et al. Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue. American journal of clinical and experimental urology 2014; 2: 313
• 37 Khurana N, Sikka SC. Interplay between SOX9, Wnt/β-catenin and androgen receptor signaling in castration-resistant prostate cancer. International journal of molecular sciences 2019; 20: 2066
• 38 Omar HA, Tolba MF. Caffeic acid phenethyl ester guards against benign prostate hypertrophy in rats: Role of IGF-1R/protein kinase-B (Akt)/β-catenin signaling. IUBMB life 2018; 70: 519-528
• 39 Wang Z, Yang S, Li Y. et al. Simvastatin improves benign prostatic hyperplasia: role of peroxisome-proliferator-activated receptor-γ and classic WNT/β-catenin pathway. International Journal of Molecular Sciences 2023; 24: 4911
• 40 Zhang M, Luo C, Cui K. et al. Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. World journal of urology 2020; 38: 2933-2943
• 41 Froment P, Gizard F, Defever D. et al. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. Journal of Endocrinology 2006; 189: 199-209
• 42 Sato H, Sugai H, Kurosaki H. et al. The effect of sex hormones on peroxisome proliferator-activated receptor gamma expression and activity in mature adipocytes. Biological and Pharmaceutical Bulletin 2013; 36: 564-573
• 43 Choi YJ, Kim EK, Fan M. et al. Effect of Paecilomyces tenuipes extract on testosterone-induced benign prostatic hyperplasia in Sprague–Dawley rats. International Journal of Environmental Research and Public Health 2019; 16: 3764
• 44 Abo-El Fetoh ME, Abdel-Fattah MM, Mohamed WR. et al. Cyclooxygenase-2 activates EGFR–ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia. Inflammopharmacology. 2023; 31: 499-516
• 45 Canda AE, Mungan MU, Yilmaz O. et al. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. International urology and nephrology 2006; 38: 275-280
• 46 Giatti S, Cioffi L, Diviccaro S. et al. Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level. Journal of Endocrinological Investigation. 2024: 1
• 47 Traish AM. Health risks associated with long-term finasteride and dutasteride use: it&apos;s time to sound the alarm. The World Journal of Men&apos;s Health 2020; 38: 323
• 48 Tong Y, Zhou RY. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation 2020; 2020: 7958316
• 49 Schweizer MT, Haugk K, McKiernan JS. et al. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PloS one 2018; 13: e0198389
• 50 Katleba KD, Tsamouri MM, Jathal M. et al. Androgen receptor-dependent regulation of metabolism in high grade bladder cancer cells. Scientific reports 2023; 13: 1762
• 51 Biersack B. The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides. International Journal of Molecular Sciences 2024; 25: 5977
• 52 Kang B, Mottamal M, Zhong Q. et al. Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer. Pharmaceuticals. 2023; 16: 735
• 53 Yu X, Liu F, Zeng L. et al. Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells. Cellular Physiology and Biochemistry 2018; 47: 957-971
• 54 Omran MM, Kamal MM, Ammar YA. et al. Pharmacological investigation of new niclosamide-based isatin hybrids as antiproliferative, antioxidant, and apoptosis inducers. Scientific Reports 2024; 14: 19818
• 55 Guo Y, Zhu H, Xiao Y. et al. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death & Disease 2022; 13 p 112
• 56 Manna MJ, Abu-Raghif A, Muhsin HY. The effect of Niclosamide in acetic acid induce colitis: an experimental study. Prensa méd. argent.. 2019: 309-316
• 57 Hernandez-Quiles M, Broekema MF, Kalkhoven E. PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Frontiers in endocrinology 2021; 12: 624112
• 58 Sharma V, Patial V. Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases. Frontiers in Pharmacology 2022; 13: 991059
• 59 Faheem SA, Hazem RM, Elsayed NM. et al. Niclosamide modulates cyclosporin A-induced hepatotoxicity in a mouse model: PPAR-γ and Wnt/β-catenin crosstalk. International Immunopharmacology 2023; 117: 109941
• 60 Percie du Sert N, Hurst V, Ahluwalia A. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Journal of Cerebral Blood Flow & Metabolism 2020; 40: 1769-1777